Treatment of major depressive disorder using botulinum toxin a: A 24-week randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 75, Issue 8, 2014, Pages 837-844

  Magid, Michelle ^a   Reichenberg, Jason S ^b   Poth, Poppy E ^c   Robertson, Henry T ^c   LaViolette, Amanda K ^b   Kruger, Tillmann H C ^d   Wollmer, M Axel ^e,f,g  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SETON FAMILY OF HOSPITALS   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e Budapest An der Schön Klinik Hamburg Eilbek Dehnhaide   (Germany)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; COSMETIC; PLACEBO; MUSCLE RELAXANT AGENT;

ADULT; AGED; BECK DEPRESSION INVENTORY; CONFERENCE PAPER; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DSM-IV; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PSYCHOTHERAPY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SCORING SYSTEM; SYMPTOMATOLOGY; ADOLESCENT; ARTICLE; CONTROLLED CLINICAL TRIAL; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXINS, TYPE A; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908332158     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.13m08845     Document Type: Conference Paper

References (23)

1. Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.
2. World Health Organization (WHO) fact sheet on depression. WHO Website. http://www.who.int/mediacentre/factsheets/fs369/en/. Updated October 2012. Accessed July 10, 2013.
3. Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32(5):645-649, discussion 649-650.
4. Wollmer MA, De Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. JPsychiatr Res. 2012;46(5):574-581.
5. Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial [published online ahead of print December 1, 2013]. J Psychiatr Res.
6. Ekman P, Levenson RW, Friesen WV. Autonomic nervous system activity distinguishes among emotions. Science. 1983;221(4616):1208-1210.
7. Heckmann M, Teichmann B, Schroder U, et al. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol. 2003;49(2):213-216.
8. Davis II, Senghas A, Brandt F, et al. The effects of BOTOX injections on emotional experience. Emotion. 2010;10(3):433-440.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(l):56-62.
10. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8(1):77-100.
11. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613
12. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33, quiz 34-57.
13. Honeck P, Weiss C, Sterry W, et al; Gladys study group. Reproducibility of a four-point clinical severity score for glabellar frown lines. Br J Dermatol. 2003;149(2):306-310.
14. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000;31(2):73-86.
15. Williams JBWA structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747.
16. Pinheiro J, Bates D, Deb Roy S, et al; R Core Team, nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-117. http://CRAN.R-project.org/package=nlme. 2014.
17. Alam M, Barrett KC, Hodapp RM, et al. Botulinum toxin and the facial feedback hypothesis: can looking better make you feel happier? J Am Acad Dermatol. 2008;58(6):1061-1072.
18. Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol. 2009;8(l):24-26.
19. Hennenlotter A, Dresel C, Castrop F, et al. The link between facial feedback and neural activity within central circuitries of emotion-new insights from botulinum toxin-induced denervation of frown muscles. Cereb Cortex. 2009;19(3):537-542.
20. Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology. 2010;35(1):169-191.
21. Sheline YI, Barch DM, Donnelly JM, et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an IMRI study. Biol Psychiatry. 2001;50(9):651-658.
22. Beer K. Cost effectiveness of botulinum toxins for the treatment of depression: preliminary observations. J Drugs Dermatol. 2010;9(1):27-30.
23. Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840-1847.